Overview

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals